Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Yokohama City University Medical Center |
---|---|
Information provided by: | Yokohama City University Medical Center |
ClinicalTrials.gov Identifier: | NCT00295555 |
Few studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure and regulation of sympathetic nervous activity in hypertensive patients with diabetic nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in diabetic nephropathy patients and compare the results with those in patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus Essential Hypertension Renal Failure |
Drug: Effects of doxazosin on morning surge in diabetic patients |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy |
Enrollment: | 98 |
Study Start Date: | January 2004 |
Study Completion Date: | April 2007 |
The study is an open-labeled parallel prospective trial comparing the effects of doxazosin (2-8 mg/day) on 24-h blood pressure and autonomic nervous activity. Hypertensive patients with non-insulin-dependent diabetic nephropathy, patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy undergo ambulatory blood pressure monitoring before and after treatment with doxazosin. Simultaneously, spectral analysis is performed to calculate the high frequency components as a marker of parasympathetic nervous activity, and the low frequency components/high frequency components ratios as an index of the sympathovagal balance.
Ages Eligible for Study: | 20 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Yokohama City University Center Hospital | |
Yokohama, Japan, 232-0024 |
Principal Investigator: | Gen Yasuda, MD | Yokohama City University Center Hospital |
Principal Investigator: | Gen Yasuda, MD | Yokohama City University Center Hospital |
Study ID Numbers: | 7332-2 |
Study First Received: | February 21, 2006 |
Last Updated: | May 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00295555 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
ambulatory blood pressure monitoring doxazosin alpha1-adrenergic antagonists sympathetic nervous activity |
diabetic nephropathy essential hypertension power spectral analysis morning surge |
Renal Insufficiency Diabetic Nephropathies Metabolic Diseases Diabetes Mellitus Vascular Diseases Endocrine System Diseases Doxazosin Urologic Diseases |
Essential hypertension Endocrinopathy Kidney Diseases Metabolic disorder Glucose Metabolism Disorders Diabetes Complications Kidney Failure Hypertension |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs Adrenergic Antagonists |
Cardiovascular Diseases Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |